drugset
drugset / Trial / NCT05288543

A Study of Orally Administered IPG7236 in Healthy Adult Participants

NCT05288543 ↗

Phase 1 Terminated 63 enrolled Nanjing Immunophage Biotech Co., Ltd Novotech (Australia) Pty Limited · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult participants.

Timeline

Start
2022-04-07
Primary completion
2023-03-31
Completion
2025-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject IPG7236 Unknown 25 mg Oral
Subject IPG7236 Unknown 50 mg Oral
Subject IPG7236 Unknown 100 mg Oral
Subject IPG7236 Unknown 200 mg Oral
Subject IPG7236 Unknown 300 mg Oral
Subject IPG7236 Unknown 400 mg Oral
Subject IPG7236 Unknown 500 mg Oral
Subject IPG7236 Unknown 600 mg Oral

Indications

atopic eczema